Introduction {#s1}
============

General anesthetics are unique drugs that can induce reversible unconsciousness and have been widely used for over 170 years. However, the neurophysiological mechanisms of anesthetic-induced altered states of consciousness are not completely understood. Recent electroencephalography (EEG) and neuroimaging studies significantly advanced our understanding of the brain activity during general anesthesia. Anesthetic-induced unconsciousness is now thought to be associated with profound oscillations between brain structures ([@bib35]; [@bib50]; [@bib4]; [@bib25]; [@bib10]; [@bib47]). Moreover, we recently reported that anesthetic-induced state transitions are abrupt during propofol-induced loss of consciousness (LOC) and return of consciousness (ROC) in non-human primates ([@bib25]; [@bib47]). Discrete metastable states have been reported during emergence from isoflurane in small animals ([@bib24]). Abrupt state transitions might be a fundamental manner of how the brain functions during anesthetic-induced altered states of consciousness. However, oscillatory dynamics per se during transitions and unconsciousness appear to be unique to each anesthetic agent.

Dexmedetomidine is a highly selective α2-adrenergic agonist and is unique among currently available anesthetics, most of which are known to act at multiple receptors in the central nervous system. A recent neuroimaging study suggests that dexmedetomidine significantly reduces information transfer in the local and global brain networks in humans ([@bib22]), consistent with the effect of propofol ([@bib41]). Functional disconnection between brain regions is a possible mechanism suggested for dexmedetomidine-induced unconsciousness ([@bib3]; [@bib58]). EEG changes under dexmedetomidine anesthesia are distinctive, with increased slow-delta oscillations across the scalp and increased frontal spindle oscillations, and closely approximate the dynamics during human non-rapid eye movement (NREM) sleep ([@bib4]; [@bib5]). However, direct recordings from neocortex, especially from functionally interconnected regions, with α2-adrenergic agonist are rare, despite its increasing role in clinical anesthesia. Moreover, dexmedetomidine is unique because a specific α2-adrenergic antagonist is used in veterinary medicine to reverse its sedative and anesthetic effects ([@bib55]; [@bib27]). Neuronal dynamics of awakening by the α2-adrenergic antagonist need to be studied.

Here we investigated how neuronal dynamics change during dexmedetomidine-induced LOC and ROC by directly recording from a functionally and anatomically interconnecting somatosensory (S1 and S2) and ventral premotor area (PMv) network, a well-studied corticocortical circuit, in non-human primates ([Figure 1A](#fig1){ref-type="fig"}; [@bib32]; [@bib62]; [@bib16]; [@bib18]). The PMv is known to link sensation and decision-making as well as to integrate multisensory modalities ([@bib51]; [@bib15]; [@bib16]; [@bib46]; [@bib33]; [@bib1]; [@bib52]).

![Experimental paradigm and behavioral responses.\
(**A**) Location of the recording sites. Neural recording was performed in the primary somatosensory cortex (S1, red), the secondary somatosensory cortex (S2, blue), and ventral premotor cortex (PMv, gray). CS, central sulcus; IPS, intraparietal sulcus; LS, lateral sulcus; AS, acuate sulcus, and PS, principal sulcus. (**B**) Behavioral task. Sequence of events during behavioral trials. After the start tone (pure tone 1000 Hz, 100 msec), the monkey initiated a trial by placing the hand (ipsilateral to the recording site) on the button in front of the animal. The animal was required to keep its hand on the button until the end of the trial in order to receive a liquid reward (correct response). The animal then had to release the button during the inter-trial interval (ITI). (**C**) Typical behavioral response during dexmedetomidine induction and emergence. Following the start of dexmedetomidine infusion, failed attempts (black) increased briefly before the animal completely lost the response. Top: The animal's trial-by-trial button response. Correct responses (blue), failed attempts (black), and no response (red). Bottom: Probability of the task engagement (correct responses and failed attempts, purple) and task performance (correct responses only, orange). LOC was defined as the time at which the probability of task engagement was decreased to less than 0.3, and ROC was defined as the first time, since being unconscious, at which the probability of task engagement was greater than 0.3. ROPAP was defined as the time at which the probability of task performance was returning to greater than 0.9 since being unconscious and remained so for at least 3 min. LOC is shown with a black arrow and dotted lines, ROC with a purple arrow and dotted lines, and ROPAP with an orange arrow and dotted lines (**C**). Dexmedetomidine was infused at 18 μg/kg/h for the first 10 min and then 4 μg/kg/h for 50 min (shaded area in **C**). The graphs represent one recording session in Monkey 1.](elife-57670-fig1){#fig1}

We used two macaque monkeys and performed multiple recording sessions with dexmedetomidine and an α2-adrenergic antagonist atipamezole, in addition to other control recording sessions, with a minimum recording interval of 2 days ([Table 1](#table1){ref-type="table"}). Dexmedetomidine was infused through a surgically implanted vascular port. In the sessions to examine the effect of the α2-adrenergic antagonist, atipamezole was administered while dexmedetomidine was still being infused. We recorded local field potentials (LFPs) and single unit activity using surgically implanted microelectrode arrays during dexmedetomidine-induced anesthesia and recovery. We defined LOC and two recovery endpoints, ROC and return of preanesthetic performance level (ROPAP), based on the probability of task engagement and task performance ([@bib47]; [Figure 1B,C](#fig1){ref-type="fig"}). Task engagement indicates the probability of any response initiation by the animal, including correct responses and failed attempts, and task performance represents the probability of correct responses only ([@bib68]; [@bib69]; [Figure 1C](#fig1){ref-type="fig"}).

###### Number of recording experiments in each animal.

             Recording site   Number of recording sessions               
  ---------- ---------------- ------------------------------ --- --- --- ---
  Monkey 1   S1, S2, PMv      8                              2   0   2   0
  Monkey 2   S1, PMv          9                              3   2   2   2

Note: The recording sessions were performed with a minimum interval of 2 days in each animal.

Results {#s2}
=======

We successfully determined LOC, ROC and ROPAP in all the recording sessions in both animals. Interestingly, the task response behaviors appeared fluctuating, and a performing period and a non-performing period were often rapidly alternating over the course of recovery, especially during early recovery following ROC, as shown in [Figure 1A](#fig1){ref-type="fig"} and [Figure 2A](#fig2){ref-type="fig"}.

![Distinctive neural changes are associated with α2-adrenergic agonist-induced LOC, ROC and ROPAP.\
(**A**) Behavioral response. Probability of the task engagement (purple) and task performance (orange). (**B**) Local field potentials (LFP) time-domain spectrograms in S1. (**C**) LFP time-domain spectrograms in S2. (**D**) LFP time-domain spectrograms in PMv. (**E**) Average baseline firing rates in S1 (red) and PMv (blue). Firing rates were normalized to pre-anesthetic values using Z-scores. No significant differences between pre-anesthetic average and any following time point were found (ANOVA and *post hoc* Bonferroni multiple comparison tests). (**F--H**) Averaged frequency domain power spectra in S1 (n = 9 channels, **F**), S2 (n = 11 channels, **G**) and PMv (n = 10 channels, **H**). Traces are the averaged Welch's power across channels with 95% confidence intervals shaded, during wakefulness (for one minute before anesthesia start, black), anesthesia (for one minute at the end of anesthetic infusion, blue), ROC (for one minute after ROC, red) and ROPAP (for one minute after ROPAP, cyan). Bottom lines represent those frequencies with significantly different values of average power density between awake and any other given condition as found by repeated measures ANOVA (ε-corrected p-value\<0.05) and *post hoc* Bonferroni multiple comparison test (p-value\<0.0083). (**I**) Behavioral response, spectrogram in S1 and PMv, the slow-delta (0.5--4 Hz) and alpha power (8--12 Hz) change during LOC. Power was normalized to pre-anesthetic values using Z-scores. (**J**) Behavioral response, spectrogram in S1 and PMv, the slow-delta (0.5--4 Hz) and alpha power (8--12 Hz) change during LOC with arousability testing. A series of non-aversive stimuli (ear-pulling, a loud white noise at 100 dB SPL for 5 s, and hand claps 3 times at 10 cm from face, shown with red arrows) were applied at 3, 5, and 10 min after initially detected LOC. LOC is shown with a black arrow and dotted lines, ROC with a purple arrow and dotted lines, and ROPAP with an orange arrow and dotted lines (**A--E**). Dexmedetomidine was infused at 18 μg/kg/h for the first 10 min and then 4 μg/kg/h for 50 min (gray lines in **A--E**).](elife-57670-fig2){#fig2}

Distinctive neural changes at α2-adrenergic agonist-induced LOC, ROC and ROPAP {#s2-1}
------------------------------------------------------------------------------

We first compared LFP spectrograms from the primary and secondary somatosensory cortex (S1, S2) and ventral premotor area (PMv) during the transition from wakefulness to LOC and then through recovery. During wakefulness beta oscillations were present in both cortical regions (18--25 Hz in S1 and S2, 26--34 Hz in PMv, [Figure 2B,C,D](#fig2){ref-type="fig"}; [@bib12]; [@bib21]). LOC was identified at a brief increase of the alpha power following disruption of the beta oscillations ([Figure 2B,C,D](#fig2){ref-type="fig"}, [Table 2](#table2){ref-type="table"}). Then the slow-delta oscillations appeared and remained dominant throughout anesthesia until ROC. ROC was associated with an abrupt diminishing of the slow-delta oscillations and an appearance of alpha oscillations ([Figure 2B,C,D](#fig2){ref-type="fig"}, [Table 2](#table2){ref-type="table"}). ROPAP was observed at return of the beta oscillations. The peak frequencies of the beta oscillations, however, appeared to remain significantly lower than that during wakefulness ([Figure 2F,G,H](#fig2){ref-type="fig"}). During an early recovery period following ROC, the slow-delta oscillations returned repeatedly when the animal was not engaged in the task and appeared to be coupled with the alpha oscillations. Both slow-delta and alpha oscillations disappeared when the beta activity returned, suggesting that two or more states were alternating until full functional recovery. We also found that dexmedetomidine did not significantly change the average firing rate in the S1 units nor in the PMv units ([Figure 2E](#fig2){ref-type="fig"}).

###### Characteristic oscillatory changes during dexmedetomidine-induced altered behavioral states.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Behavioral state                                                        Slow-Delta        Alpha              Beta      Spindle activity   
  ----------------------------------------------------------------------- ----------------- ------------------ --------- ------------------ --------------------------------------------
  Wakefulness                                                             minimal           absent             high      absent             [Figure 2B,C,E,F](#fig2){ref-type="fig"}\
                                                                                                                                            [Figure 4B](#fig4){ref-type="fig"}

  LOC                                                                     high with delay   transiently high   minimal   high               

  Unresponsiveness                                                        high              low                absent    high               

  ROC                                                                     minimal\*         high               absent    high               

  ROPAP                                                                   minimal           minimal            high      minimal            

  Arousal by external stimuli after LOC during dexmedetomidine infusion   minimal           transiently high   absent    NA                 [Figure 2H](#fig2){ref-type="fig"}

  Reversal by α2-adrenergic antagonist during dexmedetomidine infusion    minimal           absent             high      absent             [Figure 5B,C,E,F,G](#fig5){ref-type="fig"}
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Note: The characteristic changes of the frequency band power and spindle activity are summarized for each behavioral endpoint. \*The slow-delta power was diminished at ROC, but frequently reappeared through early recovery until ROPAP.

We then tested arousability during the period following LOC using a short series of non-aversive stimuli in separate sessions. Contrary to a regular session without stimuli ([Figure 2I](#fig2){ref-type="fig"}), we observed a brief return of task attempts following the stimuli at 3 min and 5 min after initially detected LOC ([Figure 2J](#fig2){ref-type="fig"}, [Table 2](#table2){ref-type="table"}). The slow-delta oscillations were disrupted, and a brief reappearance of alpha oscillations was observed in the spectrogram when the animal\'s task attempts returned upon the stimuli, suggesting that the slow-delta oscillations per se do not assure non-arousable state. Arousability was not observed by the same stimuli at 10 min after the initial LOC and there was no change in the oscillatory dynamics ([Figure 2J](#fig2){ref-type="fig"}).

We next investigated how dexmedetomidine affects communication across S1, S2 and PMv by examining both local and regional coherence changes. We found that beta oscillations were strongly coherent locally as well as inter-regionally between S1, S2 and PMv during awake task performance ([Figure 3A--G](#fig3){ref-type="fig"}). However, following the start of dexmedetomidine infusion, while the animal was still performing the task, these coherent beta oscillations appeared to be disrupted. Subsequent dynamics characterized by a brief appearance of alpha oscillations at LOC and evolving slow-delta oscillations seemed to be all coherent locally and inter-regionally ([Figure 3A--G](#fig3){ref-type="fig"}). During recovery, the alpha and slow-delta oscillations and the beta oscillations were also coherent inter-regionally, suggesting the network is coherent throughout anesthesia and recovery. Coherence of the beta oscillations appeared to have recovered to the awake level locally and inter-regionally at ROPAP, but the peak beta frequencies at ROPAP were still significantly lower than the awake level ([Figure 3H--M](#fig3){ref-type="fig"}).

![Oscillatory dynamics are inter-regionally coherent through α2-adrenergic agonist-induced anesthesia and recovery.\
(**A**) Behavioral response. Probability of the task engagement (purple) and task performance (orange). (**B--D**). Local field potentials (LFP) time-domain coherogram within S1 (**B**), S2 (**C**) and PMv (**D**). (**E--G**). Inter-regional LFP time-domain coherogram between S1 and S2 (**E**), S1 and PMv (**F**), and S2 and PMv (**G**). (**H--M**). Averaged frequency-domain coherence within S1 (n = 36 channel pairs, **H**), S2 (n = 55 channel pairs, **I**) and PMv (n = 45 channel pairs, **J**), and between S1-S2 (n = 99 channel pairs, **K**), S1-PMv (n = 90 channel pairs, **L**) and, S2-PMv (n = 110 channel pairs, **M**), at awake (for one minute before anesthesia start, black), anesthesia (for one minute before the end of anesthesia infusion, blue), ROC (for one minute after ROC, red) and ROPAP (for one minute after ROPAP, cyan). Coherence was averaged for a 1 min period across all pair-wise channel for each epoch. Average values are shown with shaded 95% confidence intervals. Bottom lines represent those frequencies with significantly different values of average coherence between awake and any other given condition as found by repeated measures ANOVA (ε-corrected p-value\<0.05) and *post hoc* Bonferroni multiple comparison test (p-value\<0.0083). LOC is shown with a black arrow and dotted lines, ROC with a purple arrow and dotted lines, and ROPAP with an orange arrow and dotted lines (**A--G**). Dexmedetomidine was infused at 18 μg/kg/h for the first 10 min and then 4 μg/kg/h for 50 min (gray lines in **A--G**).](elife-57670-fig3){#fig3}

There was no comparable neurophysiological change at the loss of response or at the return of response in alert behaving animals without anesthetic ([@bib25]), suggesting that behavioral changes due to satiety or motivation are unlikely to be associated with the neurophysiological changes observed during dexmedetomidine-induced LOC or ROC.

Spindle activity was highest during an early recovery period {#s2-2}
------------------------------------------------------------

We also investigated spindle oscillations during dexmedetomidine anesthesia and recovery. Spindle density was analyzed in the alpha and low beta frequencies between 9 and 17 Hz over the course of behavioral changes with dexmedetomidine ([@bib26]; [Figure 4A,B](#fig4){ref-type="fig"}). We found that spindle activity emerged prior to LOC and the spindle density initially peaked at LOC ([Figure 4B](#fig4){ref-type="fig"}, [Table 2](#table2){ref-type="table"}). Spindle activity was present through dexmedetomidine-induced unconsciousness, and then further increased upon the end of anesthetic infusion and through ROC. Spindle activity was higher when the animal was performing the task prior to ROPAP, as compared to the performing period after ROPAP where the spindles were nearly completely diminished. Moreover, the spindle activity appeared to increase at the behavioral transitions between a task responding period and a non-responding period. The power of alpha frequencies seemed to be correlating with the spindle activity during anesthesia and recovery ([Figure 4C](#fig4){ref-type="fig"}). Spindle characteristics, including density, duration and peak frequency, were largely similar between under anesthesia and during a non-performing period after ROPAP ([Figure 4D,E,F](#fig4){ref-type="fig"}). However, in S1 the spindle density was statistically significantly higher during the non-performing period after ROPAP than under anesthesia, and in S2 the density was lower during the non-performing period after ROPAP than under anesthesia ([Figure 4D](#fig4){ref-type="fig"}). Spindle duration was significantly longer during the non-performing period after ROPAP than under anesthesia ([Figure 4E](#fig4){ref-type="fig"}).

![Spindle activity increases during early recovery following α2-adrenergic agonist-induced anesthesia.\
(**A**) Behavioral response. Probability of the task engagement (purple) and task performance (orange). (**B**) Spindle density (counts/min) in 9--17 Hz in S1 (red trace), S2 (magenta trace) and PMv (blue trace). (**C**) Normalized power of alpha frequency (8--12 Hz) in S1 (red trace), S2 (magenta trace) and PMv (blue trace). (**D--F**). Spindle characteristics in S1 (top plots), S2 (middle plots) and PMv (bottom plots) of density (**D**), duration (**E**), and peak frequency (**F**). Box plots represent the median with 25^th^ and 75^th^ percentiles and single points are all values beyond. Asterisks indicate statistically significant difference (two-sided unpaired t-test, p\<0.01). Comparisons were made between the 10 min periods: awake (for the last 10 min of wakefulness before anesthesia start, black bar); anesthesia (for 10 min during anesthetic infusion, red bar); non-performing after ROPAP (for 10 min of the non-performing period, blue bar); and performing after ROPAP (for the last 10 min of the performing period, pink bar) shown in **A**. LOC is shown with a black arrow and dotted lines, ROC with a purple arrow and dotted lines, and ROPAP with an orange arrow and dotted lines (**A--C**). Dexmedetomidine was infused at 18 μg/kg/h for the first 10 min and then 4 μg/kg/h for 50 min (gray solid lines in **A--C**).](elife-57670-fig4){#fig4}

α2-adrenergic antagonist immediately restored awake dynamics and top task performance without intermediate stages {#s2-3}
-----------------------------------------------------------------------------------------------------------------

α2-adrenergic antagonist atipamezole induced an instant return of the top task performance while dexmedetomidine was still being infused ([Figure 5A](#fig5){ref-type="fig"}). Concurrently, oscillatory dynamics demonstrated discontinuous return of the robust beta oscillations at the frequencies that were shown during wakefulness ([Figure 5B,C,F,G](#fig5){ref-type="fig"}, [Table 2](#table2){ref-type="table"}). These beta oscillations were inter-regionally coherent ([Figure 5D,H](#fig5){ref-type="fig"}). In fact, the line coherogram indicated that the beta oscillations were significantly more coherent inter-regionally after α2-antagonist administration than during wakefulness ([Figure 5H](#fig5){ref-type="fig"}). The spindle activity was abruptly diminished upon the antagonist administration without showing its increase prior to ROC as observed during recovery without antagonist ([Figure 5E](#fig5){ref-type="fig"}).

![α2-adrenergic antagonist immediately restores top task performance and awake dynamics.\
(**A**) Behavioral response. Probability of the task engagement (purple) and task performance (orange). (**B**) Local field potentials (LFP) time-domain spectrogram in S1. (**C**) LFP time-domain spectrogram in PMv. (**D**) LFP time-domain coherogram between S1 and PMv. (**E**) Spindle density (counts/min) in 9--17 Hz in S1 (red trace) and PMv (blue trace). (**F**) Averaged frequency-domain power spectra in S1 (n = 10 channels), (**G**) Averaged frequency-domain power spectra in PMv (n = 11 channels). Traces are the averaged Welch's power across channels with shaded 95% confidence intervals, at awake (for one minute before anesthesia start, black), during anesthesia (for one minute immediately before α2-adrenergic antagonist injection, blue) and after antagonist (for one minute immediately following α2-adrenergic antagonist injection, cyan). Bottom lines represent those frequencies with significantly different values of average power density between awake and any other given condition (repeated measures ANOVA and *post hoc* Bonferroni multiple comparison test, p-value\<0.017). (**H**) Averaged frequency-domain coherence between S1 and PMv (n = 110 channel pairs). Average lines are shown with shaded 95% confidence intervals. Bottom lines represent those frequencies with significantly different values of average coherence between awake and any other given condition (Friedman's test and *post hoc* Bonferroni multiple comparison test, p-value\<0.017). Coherence were averaged at awake (for one minute before anesthesia start, black), during anesthesia (for one minute immediately before antagonist injection, blue) and after antagonist (for one minute immediately following α2-adrenergic antagonist injection, cyan). LOC is shown with a black arrow and dotted lines (**A--D**). Dexmedetomidine was infused at 18 μg/kg/h for the first 10 min and then 4 μg/kg/h for 50 min (gray lines and shaded area in **A--D**). α2-adrenergic antagonist atipamezole 100 µg/kg was intravenously injected after 30 min of dexmedetomidine infusion (at the time of 60 min).](elife-57670-fig5){#fig5}

To further quantify complex spectral dynamics during recovery from dexmedetomidine-induced unconsciousness, we investigated a three-dimensional (3D) state space using principal components analysis for three LFP spectral amplitude ratios ([@bib19]; [@bib24]). A low-dimensional subspace especially allows identifying key features of the state transitions, such as density of the state and velocity of the change. We focused on the recovery dynamics without α2-antagonist ([Figure 6A,C](#fig6){ref-type="fig"}) versus with α2-antagonist ([Figure 6B,D](#fig6){ref-type="fig"}). During recovery without antagonist, we found two distinct clusters with a high-density core and a number of clouds connecting these two clusters in both S1 and PMv, possibly forming an intermediate cluster ([Figure 6](#fig6){ref-type="fig"} A~1,\ 2~, C~1,\ 2~). The intermediate area corresponded to high speed values of spontaneous trajectories ([Figure 6](#fig6){ref-type="fig"} A~3~, C~3~) and mixed task responses ([Figure 6](#fig6){ref-type="fig"} A~4~, C~4~), indicating unstable transitions. Two distinct clusters appeared to be distinguished by the animal\'s task performance level, high task performance versus minimum-to-zero task response. Awakening induced by α2-antagonist atipamezole demonstrated no intermediate state and two clusters were clearly separated in the state space in S1 and PMv ([Figure 6](#fig6){ref-type="fig"} B~1,\ 2~, D~1,\ 2~). The state transition from unresponsiveness to responsiveness was discontinuous and abrupt ([Figure 6](#fig6){ref-type="fig"} B~3~, D~3~). These two clusters were exclusively associated with no response and the highest performance ([Figure 6](#fig6){ref-type="fig"} B~4~, D~4~).

![State space characterizes recovery through intermediate state without α2-antagonist and instant awakening with α2-antagonist.\
(**A1-D1**) Density plots in 3D during anesthesia and recovery without antagonist in S1 (**A~1~**) and PMv (**C~1~**) and with antagonist in S1 (**B~1~**) and PMv (**D~1~**). The density heat-map was calculated with a kernel density estimator from the scatter data created using the first principal component from the three spectral ratios described in the methods. (**A2-D2**) Density plots in 2D during anesthesia and recovery without antagonist in S1 (**A~2~**) and PMv (**C~2~**) and with antagonist in S1 (**B~2~**) and PMv (**D~2~**). (**A~3~-D~3~**) Speed plots during anesthesia and recovery without antagonist in S1 (**A~3~**) and PMv (**C~3~**) and with antagonist in S1 (**B~3~**) and PMv (**D~3~**). The speed was calculated as the Euclidean distance between consecutive points and is represented as heat-map. (**A~4~-D~4~**) Task performance during anesthesia and recovery without antagonist in S1 (**A~4~**) and PMv (**C~4~**) and with antagonist in S1 (**B~4~**) and PMv (**D~4~**). The plots are color-coded according to the task performance probability. The data were analyzed for the period between LOC and the end of recording session. Each dot corresponds to a 1 s window for all plots. Dexmedetomidine was infused at 18 μg/kg/h for the first 10 min and then 4 μg/kg/h for 50 min in all sessions. α2-adrenergic antagonist atipamezole 100 µg/kg was intravenously injected at 30 min of dexmedetomidine infusion.](elife-57670-fig6){#fig6}

Discussion {#s3}
==========

Our results demonstrate that distinctive, not gradual, neural changes were associated with the behavioral changes during α2-adrenergic agonist dexmedetomidine-induced altered states of consciousness, consistent with propofol-induced LOC and ROC ([@bib25]; [@bib47]), even though a pharmacokinetic model assures gradual change in the anesthetic concentrations ([@bib47]). Abrupt or non-linear state transitions are well known during natural sleep ([@bib54]; [@bib60]) and in epilepsy ([@bib11]). Together, these results suggest that abrupt state transitions are a fundamental manner of how the brain functions.

In the current work, a brief appearance of alpha oscillations with an increase of spindle activity was characteristic at LOC and ROC, and the slow-delta oscillations became dominant after LOC and through ROC ([Table 2](#table2){ref-type="table"}). Full task performance recovery also appeared to be associated with return of robust beta oscillations. Additionally, these characteristic oscillations were coherent locally as well as inter-regionally during anesthesia and recovery, suggesting that dexmedetomidine does not interrupt consistency of the dynamics in this cortical network. Interestingly, we have shown discrepancy between local coherence and inter-regional coherence during propofol anesthesia ([@bib25]). Especially, the high beta-gamma oscillations at propofol-induced LOC, that were highly coherent locally, were not coherent inter-regionally. Guldenmund and colleagues reported that thalamic functional connectivity within key areas of the arousal pathway was preserved during dexmedetomidine-induced unresponsiveness, but was significantly reduced during propofol anesthesia ([@bib20]). Together, these results suggest that dexmedetomidine preserves inter-regional continuity across frequencies through the state changes while propofol interrupts the communication during the state transition. The results also suggest that the distinctive neural changes in the cortical dynamics induced by α2-adrenergic agonist are likely driven by remote areas, such as subcortical regions.

Recovery from dexmedetomidine shows a characteristic intermediate state with an increase in the alpha power and high spindle density, especially during early recovery following the end of anesthetic infusion through ROC. The oscillatory dynamics of this intermediate state resembles the state of NREM and REM sleep ([@bib48]) and is finally replaced with coherent beta oscillations characteristic to wakefulness. Using pharmacogenetic techniques in mice, Zhang and colleagues reported that sleep-like sedation with α2-adrenergic agonist is mediated through the preoptic hypothalamic area, while loss of righting reflex, considered a surrogate for unconsciousness, requires locus coeruleus (LC) ([@bib72]). Observed behavioral state changes under dexmedetomidine in the current study, including unresponsiveness and an intermediate state with fluctuating task responses, are consistent with their findings of neuroanatomical sites of the dexmedetomidine action. The α2-adrenergic agonist at high concentrations blocks the release of norepinephrine from neurons projecting from LC to the extended areas, including the cortex, the thalamus and the arousal pathways, resulting in wide-spread slow-delta oscillations, consistent with the dynamics shown in the unresponsive state in our study. When the α2-adrenergic agonist concentration is decreasing following the end of anesthetic infusion, the blockade of norepinephrine release may be limited to the preoptic area, which activates inhibitory GABAergic projections in the arousal centers ([@bib72]), similar to the effects of GABAergic general anesthetic agents. Increasing GABA~A~ conductance leads to synchronous alpha-activity in the thalamocortical loops ([@bib14]), consistent with our finding of inter-regionally coherent alpha oscillations during the intermediate state in early recovery from dexmedetomidine.

Although the spindle characteristics have been shown to vary across cortical regions during sleep ([@bib61]), characteristic features of the observed spindle activities with dexmedetomidine seem to closely approximate the spindles during NREM sleep in humans and non-human primates ([@bib44]; [@bib61]), suggesting common mechanisms. In the current work, we found sustained high spindle activity following the end of anesthetic infusion. The spindle activity during this early recovery period was often higher than the one during dexmedetomidine infusion. These results suggest that, as compared to dexmedetomidine-induced anesthesia, dexmedetomidine-induced sedation or recovery from anesthesia may be neurophysiologically similar to NREM sleep. This is also consistent with the finding that dexmedetomidine activates endogenous NREM sleep-promoting pathways ([@bib43]; [@bib71]). Moreover, we found a transient increase in the spindle activity at behavioral transitions, including LOC and task response shifts during recovery. The spindles are thought to increase an arousability threshold since burst firing of thalamocortical cells during spindles blocks external stimuli ([@bib66]; [@bib8]), and the spindle increase at LOC and during unresponsiveness can be explained by this possible sleep protection mechanism. Interestingly, there are some spindle peaks observed at the transition from no-response to full-response in this study. Spindles during sleep have also been reported to increase at transitional periods out of NREM sleep ([@bib65]), suggesting another similarity of sleep spindles and the spindles with dexmedetomidine and their possible role in the state transition. Clinically, these spindles can be useful as a sign for state changes under dexmedetomidine. When the patients are anesthetized under dexmedetomidine with minimum spindle activity, monitoring the spindle activity can be preventive against lightening the anesthetic level. When conscious or arousable sedation is appropriate, constant appearance of the high spindle activity may be a goal. Human EEG under dexmedetomidine shows dominant slow-delta and alpha-theta oscillations and the spindle activity in the frontal region following LOC ([@bib4]; [@bib5]), consistent with our LFP findings. Together, forehead application of the EEG monitors could be modified for this new role of monitoring spindles under dexmedetomidine sedation and anesthesia.

Further, our results demonstrate for the first time that the use of an α2-adrenergic antagonist instantly restores awake cortical dynamics and concurrent high level of task performance. Previously, pioneer clinical studies demonstrated that an α2-adrenergic antagonist, atipamezole, reversed sedative and sympatholytic effects of dexmedetomidine in humans ([@bib28]; [@bib2]; [@bib55]). Our simultaneous intracortical neurophysiology recordings and behavioral measurements suggest an abrupt transition by the α2-adrenergic antagonist, and the awakening is neither gradual nor multi-step. The 3D state space dynamics clearly characterizes a discontinuous shift upon antagonist administration without transitioning through intermediate states. During emergence without antagonist, we found diffuse clouds or possible clusters connecting between unresponsiveness and a performing state shown in [Figure 6](#fig6){ref-type="fig"}. This intermediate state corresponds to spectrographic signatures, such as an increase in the alpha power and the spindle activities. Hudson and colleagues first reported multiple metastable states during recovery from isoflurane anesthesia in rodents ([@bib24]). Proekt and Hudson further delineated stochastic dynamics of neuronal states during anesthetic recovery and explained that anesthetic recovery can be independent from pharmacokinetics ([@bib49]). Our results with dexmedetomidine are consistent with the proposed multi-state stochastic recovery theories. However, our results also demonstrate that the probabilistic process of anesthetic recovery can be shut down by an overwhelming pharmacological effect of α2-adrenergic antagonist at the receptor level and that the intermediate recovery states can be totally bypassed. Moreover, our results support that the brain is capable to switch dynamics in an on-off manner and the expected behavioral performance can accompany without delay.

How the unconscious state can be actively reversed has been investigated in coma patients due to brain injury, but with a limited degree of behavioral recovery ([@bib56]; [@bib70]). In propofol-anesthetized humans, partial reversal of consciousness and the processed EEG index was shown by physostigmine ([@bib37]). In anesthetized rodents, activation of dopamine and norepinephrine pathways are shown to promote behavioral arousal with inhaled anesthetics ([@bib29]; [@bib63]). Gao and colleagues recently reported that activating nucleus gigantocellularis neurons in the reticular activating system elicited a high degree of awakening, including cortical, autonomic, and behavioral recovery, in both isoflurane anesthetized and hypoglycemia-induced coma rodents ([@bib17]). In these small animal studies, the level of performance recovery is not yet clear. Clinically, emergence and postoperative neurocognitive problems still affect patients undergoing surgery of all ages ([@bib34]; [@bib64]; [@bib40]) and are thought to be associated with an overall increase in morbidity and mortality ([@bib39]; [@bib59]; [@bib67]). Immediate restoration of the top task performance by an α2-adrenergic antagonist in the current study is promising and suggests its future clinical role in active awakening. Although dexmedetomidine per se has been shown to reduce emergence delirium and agitation in humans ([@bib31]; [@bib57]), it is possible that other anesthetics could benefit from active awakening and bypassing an intermediate recovery state where delirium and agitation are often observed.

The use of nonhuman primates has significant advantages in comparative neuroscience studies, including close homology in circuit architecture to humans and an ability to perform behavioral tasks that enable us to determine human-relevant behavioral endpoints during anesthesia-induced altered states of consciousness. However, there are limitations in this model. First, we used two animals due to the animal number limitations and randomization was not possible. It is also not possible to fully evaluate interindividual variability in the anesthetic effects on neuronal dynamics nor behavioral changes. Secondly, although we can prospectively determine the recording sites in nonhuman primates, intracortical neurophysiology recording sites are limited to a few sites and the recorded dynamics may not be seen in other areas. We studied a somatosensory and premotor cortical network since the network is functionally and anatomically interconnected ([@bib32]; [@bib62]; [@bib16]; [@bib18]) and the premotor area is known for cognitive functions ([@bib51]; [@bib15]; [@bib16]; [@bib46]; [@bib33]; [@bib1]; [@bib52]). Future studies are needed to examine whether the present results can be applied to more cognitively-relevant brain regions. In addition, we noticed that, in this hierachical sensory-premotor network, the observed neural changes are consistent and coherent between S1, S2 and PMv during dexmedetomidine-induced altered states of consciousness, suggesting that anesthetic effects may be more global than integrated in the neocortex ([@bib45]; [@bib36]). These findings require testing in more cognitively-relevant regions as well.

In summary, behavioral endpoints, such as LOC, ROC and full task performance recovery ROPAP, are successfully defined during α2-adrenergic agonist-induced altered states of consciousness in non-human primates, and are all associated with a distinctive change in the cortical dynamics, consistent with the abrupt state transitions during propofol anesthesia and recovery ([@bib25]; [@bib47]). The intermediate recovery state between unresponsiveness and full performance recovery is distinguished by sustained high spindle activities with rapidly fluctuating behavioral responses. Awakening by the α2-adrenergic antagonist completely eliminates the intermediate state and discontinuously restores awake neuronal dynamics and the top task performance while dexmedetomidine was still being infused. The results suggest that instant functional recovery is possible following anesthetic-induced unconsciousness and the intermediate state is not a necessary path for the brain recovery.

Materials and methods {#s4}
=====================

All animals were handled according to the institutional standards of the National Institute of Health. Animal protocol was approved by the institutional animal care and use committee at the Massachusetts General Hospital (2006N000174). We used two adult male monkeys (*Macaca mulatta*, 10--12 kg). Prior to starting the study, a titanium head post was surgically implanted on each animal. A vascular access port was also surgically implanted in the internal jugular vein (Model CP6, Access Technologies). Once the animals had mastered the following task, prior to the recording studies, extracellular microelectrode arrays (Floating Microelectrode Arrays, MicroProbes) were implanted into the primary somatosensory cortex (S1), the secondary somatosensory cortex (S2) and ventral premotor area (PMv) through a craniotomy ([Figure 1A](#fig1){ref-type="fig"}). Each array (1.95 × 2.5 mm) contained 16 platinum-iridium recording microelectrodes (\~0.5 Meg Ohm, 1.5--4.5 mm staggered length) separated by 400 µm. The placement of arrays was guided by the landmarks on cortical surface ([Figure 1A](#fig1){ref-type="fig"}) and stereotaxic coordinates ([@bib53]). A total of five arrays were implanted in Monkey 1 (2 arrays in S1, one in S2, and two in PMv in the left hemisphere) and four arrays in Monkey 2 (2 arrays in S1, one in S2, and one and PMv in the right hemisphere). S2 array in Monkey 2 did not provide stable signals due to unknown damage. The recording experiments were performed after 2 weeks of recovery following the array surgery. All experiments were conducted in radio-frequency shielded recording enclosures.

The animals were trained in the behavioral task shown in [Figure 1B](#fig1){ref-type="fig"}. After the start tone (1000 Hz, 100 msec) the animals were required to initiate each trial by holding the button located in front of the primate chair using the hand ipsilateral to the recording hemisphere. They were required to keep holding the button until the task end in order to receive a liquid reward. The monkeys were trained to perform correct response greater than 90% of the trials consistently for longer than \~1.5 hr in an alert condition. Animal's task performance during the session was monitored and simultaneously recorded using a MATLAB based behavior control system ([@bib6]; [@bib7]). The animal\'s trial-by-trial button-holding responses were used to define two metrics to allow quantification of behavioral endpoints: task engagement and task performance probability ([@bib47]). Task engagement indicates a probability of any response initiation, including correct responses and failed attempts, and task performance represents a probability of correct responses only ([@bib68]; [@bib69]; [Figure 1B,C](#fig1){ref-type="fig"}). LOC was defined as the time at which the probability of task engagement was decreased to less than 0.3, and ROC was defined as the first time, since being unconscious, at which the probability of task engagement was greater than 0.3 ([@bib13]; [@bib42]; [Figure 1C](#fig1){ref-type="fig"}). We also defined return of preanesthetic performance level (ROPAP) at which the probability of task performance was returning to greater than 0.9 since being unconscious and remained so for at least 3 min.

Dexmedetomidine was infused for total 60 min at 18 μg/kg/h for the first 10 min and then 4 μg/kg/h for 50 min through a vascular access port. The infusion rate of dexmedetomidine was determined in order to induce LOC in approximately 10 min in each animal. α2-adrenergic antagonist atipamezole (100 µg/kg) was injected through a vascular access port at 30 min of dexmedetomidine infusion while it was still being infused in four sessions and at the end of 60 min dexmedetomidine infusion in one session. No other sedatives or anesthetics were used during the experiment. The animal's heart rate and oxygen saturation were continuously monitored throughout the session (CANL-425SV-A Pulse Oximeter, Med Associates). The animals maintained greater than 94% of oxygen saturation throughout the experiments.

Neural activity was recorded continuously and simultaneously from S1, S2, and PMv through the microelectrode arrays while the animals were alert and participating in the task and throughout anesthesia and recovery. Analog data were amplified, band-pass filtered between 0.5 Hz and 8 kHz and sampled at 40 kHz (OmniPlex, Plexon). Local field potentials (LFPs) were separated by low-pass filtering at 200 Hz and down-sampled at 1 kHz. The spiking activity was obtained by high-pass filtering at 300 Hz, and a minimum threshold of three standard deviations was applied to exclude background noise from the raw voltage tracings on each channel. Action potentials were sorted using waveform principal component analysis (Offline Sorter, Plexon). The number of recordings are sumarized in [Table 1](#table1){ref-type="table"}. Recordings under dexmedetomidine anesthesia were performed eight times in Monkey 1 and 9 times in Monkey 2. In separate sessions, the recordings were performed under dexmedetomidine in the animals that were required no task performance (two sessions in Monkey 1 and 2 sessions in Monkey 2) and in the blind-folded animals that were performing the task (two sessions in Monkey 2). Arousability was tested in two sessions in Monkey 2. In addition, multiple recordings were performed in alert performing animals without anesthesia.

All LFP analyses were performed using existing and custom-written functions in MATLAB (MathWorks Inc, Natick, MA)([@bib9]). Raw signals were filtered to remove 60 Hz noise by running a 2^nd^ order Butterworth filter in each time direction. The resulting signals were subject to continuous multitaper spectral and channel-to-channel coherence analysis using the Chronux toolbox ([@bib38]). Each dataset was tested for normality by Kolmogorov-Smirnov test (limiting form), conditioning the following data and statistical treatment. Sphericity was not tested but ε-corrected values did not change the interpretation of related results. To generate the spectrograms, full-length sessions were processed by running a thirty second, non-overlapping, time window, applying three tapers. The spectral lines show the average power of all channels within an array, and 95% confidence intervals (calculated by percentile method), from one-minute epoch of each condition analyzed by Welch's power spectral density estimate. Statistical analyses on the spectral change were performed comparing the awake values, frequency by frequency, versus all conditions, using repeated measures ANOVA tests (within-subject design) and post hoc Bonferroni multiple comparisons, with a corrected significance threshold set to 0.05 divided by the number of comparisons. Channel-to-channel coherence calculations were performed running a two second, non-overlapping window. To generate coherograms we averaged all pairwise combinations within or between arrays. The average coherence for each condition was computed from one-minute epochs within each condition and it is represented as the average with 95% confidence intervals (calculated by bias-corrected bootstrap). Statistical comparisons of local and inter-regional coherence between the conditions were performed, frequency by frequency, using Friedman's tests followed by post hoc Bonferroni multiple comparisons, with a corrected significance threshold set to 0.05 divided by the number of comparisons.

Spindle detection and characterization was addressed using custom-written functions in MATLAB. We based our analysis on the methodology described by Kam and colleagues ([@bib26]) using the FMA toolbox ([@bib30]). Briefly, we bandpass-filtered the 60 Hz noise-free LFP traces in the 9--17 Hz range. Then, we located spindle-like events by detecting their start/end (filtered signal amplitude threshold set at 4 z-scores above the baseline) and peak (threshold set at 6 z-scores). Only events with a total duration between 500 and 2500 milliseconds were further analyzed. After visual confirmation and removal of artifacts (events with peak amplitudes \> 15 z-scores), we counted events located within each periods of interest: the last ten minutes before the anesthetic infusion started (awake), ten minutes during the anesthetic infusion (anesthesia), ten minutes during a performing period after ROPAP (performing in recovery) and ten minutes during a non-performing period after ROPAP (non-performing in recovery). We calculated the spindle density as number of events per minute during each period of time. The spindle peak frequency was calculated for each event's raw signal spectrogram using the Hilbert-Huang transform ([@bib23]) and obtaining their frequency of maximum power. Data for spindle characterization were analyzed with two-sided unpaired t-tests with significant threshold set at 0.01.

To characterize the dexmedetomidine-induced brain states and their transitions, a three-dimensional space was defined using three spectral power ratios ([@bib19]; [@bib47]). Briefly, we obtained three frequency-band spectral power ratios (Ratio1 = power~17-35\ Hz~/power~0.5-60\ Hz~, Ratio2 = power~1-8\ Hz~/power~1-16\ Hz~ and Ratio3 = power~9-15Hz~/power~1-16\ Hz~) from each channel. For each region and ratio, data were concatenated in a time-by-channel matrix and subjected to principal component analysis (PCA). The first principal component (PC1) explained more than 70% of the data's variance. To reduce instant variability, we smoothed the PC1 values by running a 20 s Hanning window. All figures are scatter representations of the three ratios' PC1s where each point represents one second of time. The data density was calculated with a kernel density estimator function. The speed was calculated as the Euclidean length between consecutive points. The engagement plots represent the same values of probability calculated above. The data were analyzed for the period between LOC and the end of recording session.
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

This paper reports on the use of sophisticated recordings and analyses of cortical electrical activity in non-human primates and provides very new information on the changes in brain functioning that accompany sedation by an anesthetic agent called dexmedetomidine. Its originality resides in the fact that different consciousness states were studied, including the return of consciousness after the administration of a dexmedetomidine antagonist, and in the way the authors analyzed the recorded data, providing a real dissection of the recorded electrical signal. The reported results constitute a step further in the understanding of the mechanisms of anesthesia, and on the neural correlates of consciousness itself.

**Decision letter after peer review:**

Thank you for submitting your article \"Neural signatures of α2 adrenergic agonist-induced unconsciousness and awakening by antagonist\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, including Vincent Bonhomme as the Reviewing Editor and Reviewer \#1, and the evaluation has been overseen by Richard Ivry as the Senior Editor The following individuals involved in review of your submission have agreed to reveal their identity: Adrian M Owen (Reviewer \#2); Mervyn Maze (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

We would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). Specifically, we are asking editors to accept without delay manuscripts, like yours, that they judge can stand as *eLife* papers without additional data, even if they feel that they would make the manuscript stronger. Thus the revisions requested below only address clarity and presentation.

Summary:

In this study, the authors have repeated their earlier local field potential spectrographic study on propofol. They record local field potentials and single unit activity in primary sensory cortex (S1) and ventral premotor area (PMv) through surgically-implanted microelectrode arrays in two adult macaque monkeys receiving a dexmedetomidine infusion. In addition to the waking state, recordings occurred during different altered brain states, including what they define as absence of consciousness (LOC = absence of a previously learned task performance), return of consciousness (ROC = return of task engagement), and return of preanesthetic performance level (ROPAP). They also performed recording after the administration of atipamezole, an antagonist of dexmedetomidine, inducing a return to awake behavior while maintaining the dexmedetomidine infusion. This last condition is an originality as compared to the previous study with propofol, which does not have a specific reversal agent.

They found spectrogram changes that were specific to LOC (disruption of beta oscillations, brief increase of alpha, and lasting slow delta, disruption of S1-MPv beta coherence, with alpha and slow-delta S1-MPv coherence), ROC (diminishing of slow-delta, appearance of alpha, alternating alpha and delta when performing task or not, S1-MPv alpha, beta, and slow-delta coherence present; same when giving stimuli during LOC and animal performing the task), and ROPAP (return of beta with lower peak frequencies than during wakefulness, inter-regionally coherent). The observed changes were not noticed during absence of task performance in the absence of anesthetic, suggesting that the observed changes are specific to the anesthetic-induced alteration of brain state. Finally, the authors modeled the brain states during recovery in the absence of antagonist, and recovery with antagonist, using a 3D space, three spectral power ratios, and principal component analysis. They found that recovery without antagonist was characterized by unstable dynamics, while the antagonist allows bypassing this intermediate state. They conclude that instantaneous functional recovery is possible following anesthetic-induced unconsciousness and that an intermediary state is not mandatory for the brain to recover.

This is an interesting and technically impressive study. The authors used a multitaper analysis to arrive at high-resolution spectral estimates. Their new findings (e.g. difference in inter-regional coherence) may provide a foundational framework to understand the pharmacological properties of propofol vs. dexmedetomidine. Their study offers new information on the brain functional changes induced by the alpha2-agonist dexmedetomidine in primates, and on transitions between those states.

There are a number of issues that require revision.

Essential revisions:

1\) The paper is hard to follow in some places regarding what recordings were performed, in which order, and in which animal, all the more since the Materials and methods section is the last section. Figure 1 is informative on the study design, but does not provide enough details. The sequence of events should be better described. It is also difficult to know if the results presented in the manuscript are from one animal or both animals. Our understanding was that the results were primarily a repeated measures performed in the same animal, but we may be wrong. The authors may wish to create a table to summarize all this information (e.g., number of replicates for each animal) at a glance, for the sake of precision and clarity.

2\) In the previous study a total of 29 replicates were performed on the two animals during propofol anesthesia but only 17 in the current study with dexmedetomidine. What is the reason for this discrepancy?

3\) It is unclear why the data from S2 are not reported here. We understand that you reported these data separately with respect to your earlier work with propofol. However, we believe inclusion of the data from S2 would make for a more comprehensive picture and, thus increase the impact value of this paper. Unless there is a good reason to exclude these data, we recommend their inclusion.

4\) The number and sites of the implanted arrays in monkeys 1 and 2 appear to be identical to monkeys E and H reported in the earlier propofol study (Ishizawa et al., 2016; and Patel et al., 2020 if reporting S2). While appreciating that the focus in the current paper should be on dexmedetomidine, we see potential value in making a direct comparison of spectral estimates between dexmedetomidine and propofol, assuming the same two animals were used for both reports.

5\) The authors claim that neurocognitive problems occurring during anesthetic emergence could be avoided by appropriate antagonism. This has to be qualified by the fact that antagonists may induce withdrawal problems (and this can be the case after prolonged sedation by dexmedetomidine in the ICU), and may have short elimination half-lives to prevent risk of a return to sedation and/or fluctuating brain state after their administration (a good example is the one of naloxone to antagonize the effects of opioids). In addition, restoration of task performance by an antagonist does not necessarily mean full recovery of cognitive functions (cognitive alterations after anesthesia in human subjects may be subtle, and are certainly not limited to the ability to perform a task). We are also surprised by the authors\' remarks about emergence delirium/agitation as the clinical literature is replete with reports that EA/ED is reduced by dexmedetomidine in the absence of reversal by antagonism (PMID: 31391001; PMID: 30936683). Therefore, the use of Atipamezole after dexmedetomidine to reduce EA/ED appears not to be warranted.

6\) Issues that should be discussed:

a\) Although multiple measures were made, only two animals were used for the study. We understand that this may be due to technical constraints, and the difficulty of implanting monkeys with electrodes and training them for task. Nonetheless, this is a limitation of the study, and should be discussed.

b\) Recordings were limited to a specific somatosensory network, and the observed changes may not apply to other networks involved in consciousness phenomena. This should be discussed.

7\) In this study, the ROC state is considered as a recovery state, and this is logical as it follows a period of absence of behavioral response. However, steady-state dexmedetomidine sedation, and even deep sedation, in humans is characterized by the ability to rapidly restore cooperativeness upon external stimulation. Hence, the presence of a fluctuating brain state is probably a matter of plasma or effect-site concentration, may persist, and is characteristic of dexmedetomidine sedation as compared to other sedative agents such as propofol. It has been demonstrated in human functional brain imaging studies, that at comparable levels of consciousness alteration (namely unresponsiveness), dexmedetomidine effect on the brain is characterized by a relative preservation of functional connectivity between the thalamus, the mesopontine area, and the anterior cingulate cortex, as compared to propofol sedation and sleep (see, for example, Guldenmund et al., 2017). This preservation (because concerning connectivity between the thalamus and key nodes of arousal and saliency detection) is hypothesized to be responsible for the ability of the brain to switch from one state to another. This seems to be in line with the hypothesis of the authors mention in paragraph two of the Discussion section. Can the authors link their findings to these other results?

8\) With the same idea in mind, it is not clear whether the authors observed the same changes -- for the studied parameters -- during the ROC "up" and "down" brain states as during the changes in brain state induced by external stimulation, for all recorded parameters. Please clarify. This will be important in evaluating the idea that the ability of the brain to switch from one state to the other under dexmedetomidine sedation depends on the received dose, and that, when this occurs, the switch is abrupt.

9\) For the sake of clarity and ease of reading, a table may be useful in summarizing the different findings for each parameter in a given brain state (namely: wake state, LOC, ROC, ROPAP, recovery after antagonist, and arousal by external stimulation).

10\) The 3D state space model is complex and not easy to understand for readers that are not familiar with those concepts. It would be helpful to provide a short explanation on the physiological significance of the model.

11\) The ability to restore responsiveness through the activation of arousal pathways (in this case, cholinergic ones) has also been described in human subjects under constant levels of propofol or sevoflurane anesthesia (see the publications of Plourde, Meuret, et al.), with corresponding electrophysiological and functional changes. It would be interesting to discuss the findings of the present study at the light of those previous studies.

12\) We would like the authors to explain a little more clearly why they think spindle activity behaved as it did through the task. e.g. "We found that spindle activity emerged prior to LOC and the spindle density initially peaked at LOC. Spindle activity was present through dexmedetomidine-induced unconsciousness, and then further increased upon the end of anesthetic infusion and through ROC (Figure 4B). Spindle activity remained higher when the animal was performing the task prior to ROPAP, as compared to the performing period after ROPAP where the spindles were nearly completely diminished". The authors do describe again this spindle activity in the Discussion, but some more nuanced explanation of why they think they see this pattern of spindle change would be welcome. To be clear, we don\'t have a problem with what they report, we just found it rather curious and would be interested in their further thoughts.

13\) According to Aho et al. (PMID: 8100428) the optimal reversal ratio is 40:1. Using a 10 min dexmedetomidine infusion at 18 µg/kg/h and a 20 min infusion at 4 µg/kg/h, we estimate that a total of \~4 µg/kg of dexmedetomidine was infused prior to the administration of 100 µg/kg of atipamezole (ratio of 25:1). How did the authors decide on the dose of atipamezole and would they expect a different response had they used an even lower ratio of atipamezole:dexmedetomidine?
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Author response

> Essential revisions:
>
> 1\) The paper is hard to follow in some places regarding what recordings were performed, in which order, and in which animal, all the more since the Materials and methods section is the last section. Figure 1 is informative on the study design, but does not provide enough details. The sequence of events should be better described. It is also difficult to know if the results presented in the manuscript are from one animal or both animals. Our understanding was that the results were primarily a repeated measures performed in the same animal, but we may be wrong. The authors may wish to create a table to summarize all this information (e.g., number of replicates for each animal) at a glance, for the sake of preciseness and clarity.

We thank the reviewers for raising this point. We have added more details in the Figure 1 legend, and have created a table to summarize the number of various experimental sessions as suggested by the reviewers (Table 1 in a revised manuscript).

As shown in Table 1, recording experiments were repeated in the same animals using the same protocol. A set of results presented in each figure (e.g. behavioral response, spectrograms, and coherence) represents one session from one animal. These time-series data are not able to average across sessions or animals because the animal's behavioral responses, such as LOC and ROC, are unique to each session. We therefore analyzed all individual sessions, but are only presenting representative sessions in the figures. Nevertheless, we averaged signals from multi-channels in the same site (the same array) in the same session. We have added this information in the figure legends (Figure 1-5).

> 2\) In the previous study a total of 29 replicates were performed on the two animals during propofol anesthesia but only 17 in the current study with dexmedetomidine. What is the reason for this discrepancy?

In each recording session, we only used a single anesthetic agent. We performed recording with an anesthetic 1-2 times in a week with an interval of at least 2 days. Recording sessions with dexmedetomidine were performed completely separately from propofol sessions and therefore the numbers of experiments that we were able to perform were different. With dexmedetomidine, we performed more than several recording sessions in each animal shown in Table 1. We understand that the number of the sessions are sufficient for analyzing neurophysiological data and characterizing their behavioral responses.

> 3\) It is unclear why the data from S2 are not reported here. We understand that you reported these data separately with respect to your earlier work with propofol. However, we believe inclusion of the data from S2 would make for a more comprehensive picture and, thus increase the impact value of this paper. Unless there is a good reason to exclude these data, we recommend their inclusion.

We thank the reviewers for raising these concerns. We agree that the data from S2 would make a more comprehensive picture for network dynamics. In the initial manuscript submission, we did not include the data recorded from S2 arrays because an S2 array in Monkey 2 did not provide stable signals due to unknown damage and the data were not analyzed. In the revised manuscript, we have included the data from S2 in Monkey 1 and added to Figure 2, 3 and 4.

Overall the results from S2, including spectral dynamics, coherence and spindle activity, are consistent with the S1 results. Together, the revised results suggest that dexmedetomidine preserves inter-regional continuity across frequencies in this neocortical network through the state changes: an interesting comparison with propofol that appears to interrupt the network communication.

> 4\) The number and sites of the implanted arrays in monkeys 1 and 2 appear to be identical to monkeys E and H reported in the earlier propofol study (Ishizawa et al., 2016; and Patel et al., 2020 if reporting S2). While appreciating that the focus in the current paper should be on dexmedetomidine, we see potential value in making a direct comparison of spectral estimates between dexmedetomidine and propofol, assuming the same two animals were used for both reports.

We thank the reviewers for raising this point. As pointed out by the reviewers, we used the same two animals as in our previous study (Ishizawa et al., 2016), but used numerical numbering as suggested by an expert.

We agree that it is valuable to make a direct comparison of the spectral estimates between anesthetic agents, so that we could characterize different neural processes by different agents better. Since we have already reported the detailed dynamics for propofol-induced altered states of consciousness (Ishizawa et al., 2016 and Patel et al., 2020), we plan to perform focused analyses on the agent difference in a future manuscript.

> 5\) The authors claim that neurocognitive problems occurring during anesthetic emergence could be avoided by appropriate antagonism. This has to be qualified by the fact that antagonists may induce withdrawal problems (and this can be the case after prolonged sedation by dexmedetomidine in the ICU), and may have short elimination half-lives to prevent risk of a return to sedation and/or fluctuating brain state after their administration (a good example is the one of naloxone to antagonize the effects of opioids). In addition, restoration of task performance by an antagonist does not necessarily mean full recovery of cognitive functions (cognitive alterations after anesthesia in human subjects may be subtle, and are certainly not limited to the ability to perform a task). We are also surprised by the authors\' remarks about emergence delirium/agitation as the clinical literature is replete with reports that EA/ED is reduced by dexmedetomidine in the absence of reversal by antagonism (PMID: 31391001; PMID: 30936683). Therefore, the use of Atipamezole after dexmedetomidine to reduce EA/ED appears not to be warranted.

We thank the reviewers for raising these concerns. We also thank the reviewers for bringing these articles to our attention. We have revised this Discussion based on the following points and have cited these references.

We agree that antagonists may induce withdrawal problems, may cause over-antagonism, or may induce delayed re-sedation, as suggested by the reviewers. Those effects are unfortunately all "inappropriate" antagonism. The successful 𝛼2-adrenergic antagonism we show here is, although it is limited to this experimental condition, future possible "appropriate" antagonism to the anesthetic action by an 𝛼2 adrenergic agonist. For other general anesthetics, which actions are mediated through multiple neuronal receptors, finding "appropriate" antagonism will be significantly more challenging.

We also agree that the full task performance recovery in the current study does not necessarily indicate full recovery of cognitive functions. Task performance recovery may indicate a part of cognitive recovery, including attention and psychomotor speed to a limited extend, but not at all executive functions and memory: the functions that often affect humans following anesthesia and surgery. However, we think that our behavioral endpoint is one of the closest surrogates reported to date for recovery of cognitive functions in the animal models. Future studies with recording in more cognitively-relevant brain regions should analyze this question in detail. We have included this Discussion in the new paragraph that discussed the limitation of the study.

> 6\) Issues that should be discussed:
>
> a\) Although multiple measures were made, only two animals were used for the study. We understand that this may be due to technical constraints, and the difficulty of implanting monkeys with electrodes and training them for task. Nonetheless, this is a limitation of the study, and should be discussed.
>
> b\) Recordings were limited to a specific somatosensory network, and the observed changes may not apply to other networks involved in consciousness phenomena. This should be discussed.

We thank the reviewers for raising these fundamental issues. As for representativeness, we adhere to the animal number limitations required for non-human primate research and performed as many recording sessions as animal safety and usage standards allowed. Randomization was not possible at the level of treatment given to the animals. However, we were able to perform multiple control sessions where no anesthetic drug was given as we published previously (Ishizawa et al., 2016).

We prospectively determined the areas of recording based on the scientific questions we proposed. We do agree with the reviewers that the observed changes may not be seen in other networks more involved in consciousness and cognitive functions. At the same time, the ventral premotor area (PMv) has been shown to represent some of the cognitive functions, such as subjective sensory experience and decision-making in a multiple studies (de Laufuente et al., 2006, Haegens et al., 2011, Romo and de Lafuente, 2013). In addition, in this hierachical sensory network, the observed dynamics are consistent and coherant in both S1 and PMv during the anesthetic-induced altered states of consciousness, suggesting that anesthetic effects may be more global than integrated.

We have added a new paragraph to discuss these limitations.

> 7\) In this study, the ROC state is considered as a recovery state, and this is logical as it follows a period of absence of behavioral response. However, steady-state dexmedetomidine sedation, and even deep sedation, in humans is characterized by the ability to rapidly restore cooperativeness upon external stimulation. Hence, the presence of a fluctuating brain state is probably a matter of plasma or effect-site concentration, may persist, and is characteristic of dexmedetomidine sedation as compared to other sedative agents such as propofol. It has been demonstrated in human functional brain imaging studies, that at comparable levels of consciousness alteration (namely unresponsiveness), dexmedetomidine effect on the brain is characterized by a relative preservation of functional connectivity between the thalamus, the mesopontine area, and the anterior cingulate cortex, as compared to propofol sedation and sleep (see, for example, Guldenmund et al., 2017). This preservation (because concerning connectivity between the thalamus and key nodes of arousal and saliency detection) is hypothesized to be responsible for the ability of the brain to switch from one state to another. This seems to be in line with the hypothesis of the authors mention in paragraph two of the Discussion section. Can the authors link their findings to these other results?

We thank the reviewers for bringing this important article to our attention. We agree that preserved thalamic connectivity with key areas of arousal networks may explain the observed early recovery (return of response) following dexmedetomidine anesthesia. This may also explain the dynamics are able to fluctuate following dexmedetomidine, as opposed to propofol. However, the mechanisms of these characteristic dynamics are not entirely clear. This characteristic intermediate state could be generated by thalamus or sub-thalamic regions, which require future neurophysiology recordings in a broader network.

We have revised the discussion and have included the reference.

> 8\) With the same idea in mind, it is not clear whether the authors observed the same changes -- for the studied parameters -- during the ROC "up" and "down" brain states as during the changes in brain state induced by external stimulation, for all recorded parameters. Please clarify. This will be important in evaluating the idea that the ability of the brain to switch from one state to the other under dexmedetomidine sedation depends on the received dose, and that, when this occurs, the switch is abrupt.

We thank the reviewers for pointing out this issue. We did not use external stimulation during recovery, and therefore we do not know whether the fluctuating dynamics during recovery, especially the "up" brain state, is the same as the change possibly induced by external stimulation. However, in the arousability testing, we applied a series of non-aversive external stimuli (ear-pulling, a loud white noise at 100 dB SPL for 5 sec, and hand claps 3 times at 10 cm from face) at 3, 5, and 10 minutes after initially detected LOC (Figure 2J, as compared to Figure 2I). We found a brief return of task attempts with an appearance of alpha oscillations at 3 and 5 minutes, but not at 10 minutes. The brief appearance of alpha oscillations itself seems to be consistent the alpha appearance at ROC and during early recovery (Table 2).

> 9\) For the sake of clarity and ease of reading, a table may be useful in summarizing the different findings for each parameter in a given brain state (namely: wake state, LOC, ROC, ROPAP, recovery after antagonist, and arousal by external stimulation).

We thank the reviewers for the suggestion. We have added the table for the results of oscillatory dynamics changes during dexmedetomidine-induced altered behavioral states (Table 2 in the revised manuscript).

> 10\) The 3D state space model is complex and not easy to understand for readers that are not familiar with those concepts. It would be helpful to provide a short explanation on the physiological significance of the model.

We thank the reviewers for raising the issue. We have added a short explanation on the physiological importance of the state space analysis in the Results section.

Briefly, as you know, the transitions between states often show continuous and dynamic changes in time, sometimes in very fast and non-unidimensional ways. We applied the dimensionality reduction of interesting frequency ratios through principal components analysis, which allows identifying key features of the state transitions, such as density of the state and velocity of the change. And we are able to overlay other analytical or behavioral measurements on top of these low dimensional subspace to observe and decide which of them may or not be significative.

> 11\) The ability to restore responsiveness through the activation of arousal pathways (in this case, cholinergic ones) has also been described in human subjects under constant levels of propofol or sevoflurane anesthesia (see the publications of Plourde, Meuret, et al.), with corresponding electrophysiological and functional changes. It would be interesting to discuss the findings of the present study at the light of those previous studies.

We thank the reviewers for bringing this article to our attention. We have revised the Discussion and cited the reference.

> 12\) We would like the authors to explain a little more clearly why they think spindle activity behaved as it did through the task. e.g. "We found that spindle activity emerged prior to LOC and the spindle density initially peaked at LOC. Spindle activity was present through dexmedetomidine-induced unconsciousness, and then further increased upon the end of anesthetic infusion and through ROC (Figure 4B). Spindle activity remained higher when the animal was performing the task prior to ROPAP, as compared to the performing period after ROPAP where the spindles were nearly completely diminished". The authors do describe again this spindle activity in the Discussion, but some more nuanced explanation of why they think they see this pattern of spindle change would be welcome. To be clear, we don\'t have a problem with what they report, we just found it rather curious and would be interested in their further thoughts.

We thank the reviewers for bringing up this issue. We have revised the Discussion to better explain possible spindle roles based on the similarities to sleep spindles. We agree that the observed spindles activity over the course was interesting. Overall, our findings agree with the spindle's role of sleep protection. Observed increases in the spindle activity at transitional periods from non-performing to performing during recovery is indeed interesting. This could be a new role as reported by Vyazovskiy and colleagues in small animals. However, it would be difficult to discuss the mechanistic aspects of the spindles in more detail since our data are limited to the cortical regions.

> 13\) According to Aho et al. (PMID: 8100428) the optimal reversal ratio is 40:1. Using a 10 min dexmedetomidine infusion at 18 µg/kg/h and a 20 min infusion at 4 µg/kg/h, we estimate that a total of \~4 µg/kg of dexmedetomidine was infused prior to the administration of 100 µg/kg of atipamezole (ratio of 25:1). How did the authors decide on the dose of atipamezole and would they expect a different response had they used an even lower ratio of atipamezole:dexmedetomidine?

We thank the reviewers for pointing out this dosing issue. In the current work, we followed the dose reported in healthy humans by Scheinin et al., 1998. The authors reported that the dose of atipamezole needed to reverse the sedative effect of dexmedetomidine was 104+/-44 µ/kg. They also reported the dose dependent effect using 3 different dose (15, 50 and 150 µ/kg). We expect a different response with a lower dose of atipamezole. However, we were not able to perform dose-response experiments due to the animal use and recording schedule constraints.
